The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Organizer: Hidetoshi Arima (Sch. Pharm., Daiichi Univ. Pharm.), Masakazu Sekijima (Dept. Comp. Sci., Science Tokyo)

Artificial Intelligence (AI) has streamlined the traditional enormously costly and time-consuming processes in the field of drug development and has made significant achievements in improving the success rate of molecular design, target identification, and clinical trials. AI has also enabled the analysis of vast amounts of data and the design of new molecules, greatly improving the ability to explore the chemical space. This symposium will focus on AI-based drug discovery, drug formulation/DDS, and medicine, and will present the latest research results and applications by experts in academia. Dr. Masakazu Sekijima (Institute of Science Tokyo) will describe a new approach to improve the efficiency of drug discovery through the development of molecular design and generation models based on protein-ligand interactions. Dr. Yoshihiro Yamanishi (Nagoya University) will introduce the development of machine learning technology for fusion analysis of multi-omics data and chemical information, and its potential for target discovery of drug candidate compounds and prediction of adverse drug reactions. Dr. Manabu Kano (Kyoto University) will present examples of AI and machine learning applications in drug formulation technology, explaining applications of virtual measurement technology, transfer learning, design space construction, and feedback control technology. Dr. Hidetoshi Arima (Daiichi University of Pharmacy) will introduce his research results on AI-based mRNA-encapsulated LNP and cyclodextrin supramolecular design, and outline new developments in medical AI and medical DX. Through this symposium, we would like to explore the future of drug discovery, pharmaceutics/DDS, and medicine brought about by AI, as well as discuss challenges and solutions presented by AI technology, and explore possibilities for further development of drug development and medical care in Japan and collaboration between industry, government, and academia.